 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Can all cancer patients be treated with the same dose of pembrolizumab?

J Immunother Cancer: Can all cancer patients be treated with the same dose of pembrolizumab?

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

surface world

application

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The dosing regimen of pembrolizumab is completely based on the pharmacokinetic (PK) model from phase I-III trials

The purpose of this research is to determine the factors that affect PK and their relationship with clinical outcomes in the real environment

Aims to determine the factors that affect PK and its relationship with clinical results in the real environment

Recruited patients with advanced cancer who received pembrolizumab monotherapy (2 mg/kg Q3W or 200 mg/m2 Q3W), continuously sampled to obtain trough concentrations, generated a PK model, assessed covariate effects, and conducted internal procedures through a guided procedure Verification

immunity

Standard goodness of fit of pembrolizumab PK model

A total of 588 serum samples were collected from 122 patients with non-small cell lung cancer ( NSCLC ), malignant pleural mesothelioma (MPM), melanoma, and urothelial cell carcinoma (UCC) for analysis

NSCLC median follow-up for 2.

For NSCLC patients and MPM patients, there is a significant reverse CL-OS relationship

In summary, the high inter-patient variability of pembrolizumab pharmacokinetics is determined by BSA and serum albumin (on CL) and LDH (on Vd)

Among patients with high Paim monoclonal antibody pharmacokinetic variability by BSA and serum albumin (in CL) and LDH (on Vd) determined NSCLC and MPM patients showed a strong inverse relationship between CL-OS can not All patients use the same dose of pembrolizumab, and individual application doses need to be explored

Original source:

Hurkmans Daan P,Sassen Sebastiaan DT,de Joode Karlijn et al.

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.